Reducing renal function assessment prior to platinum-based chemotherapy: a real-world evaluation
DOI:
https://doi.org/10.2340/1651-226X.2024.23960Keywords:
platinum-based chemotherapy, carboplatin, cisplatin, renal functionAbstract
Background: Platinum-based chemotherapy, a widely used backbone of systemic cytotoxic anticancer treatment, is associated with nephrotoxicity. Currently, renal function is generally assessed prior to each administration of cisplatin or carboplatin, but there is no guideline regarding the frequency of renal function determination.
Objective: The primary objective was to determine the median time to a clinically relevant dosage adjustment (>10%) due to change in renal function in patients treated with cisplatin and carboplatin. Secondly, variables influencing changes in renal function were assessed.
Methods: We conducted a retrospective analysis of serial renal function assessments in platinum-treated patients with cancer in two academic medical centers, using a query to extract data from the electronic health records between 2017 and 2019.
Results: In total, 512 patients receiving cisplatin and 628 patients receiving carboplatin were included. In total, 15% of all cisplatin-treated patients were found to have a renal function less than 60 mL/min at least once during treatment, with a median time to renal function decline of 67 days (range 5-96 days), which did not differ between treatment regimens. For carboplatin 21% of patients were found to have had a dosage variation of more than 10% at least once during treatment, with a median time-to-event period of 64 days (range 5-100 days).
Interpretation: Dose adjustments during platinum-based chemotherapy resulting from renal function decline occur after a median time of ≥64 days. Our data provide substantiated guidance to recommend renal function assessment during platinum-based chemotherapy in clinically stable patients to once every 3 weeks.
Downloads
References
Launay-Vacher V, Janus N, Deray G. Renal insufficiency and cancer treatments. ESMO Open. 2016 Aug 18;1(4):e000091.
https://doi.org/10.1136/esmoopen-2016-000091 DOI: https://doi.org/10.1136/esmoopen-2016-000091
Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007 Sep 15;110(6):1376–84.
https://doi.org/10.1002/cncr.22904 DOI: https://doi.org/10.1002/cncr.22904
Janus N, Oudard S, Beuzeboc P, et al. Prevalence of renal insufficiency in cancer patients: data from the IRMA-2 study. J Clin Oncol 2009;27:15s.
https://doi.org/10.1200/jco.2009.27.15_suppl.9559 DOI: https://doi.org/10.1200/jco.2009.27.15_suppl.9559
Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol. 2010 Nov;30(6):548–56.
https://doi.org/10.1016/j.semnephrol.2010.09.003 DOI: https://doi.org/10.1016/j.semnephrol.2010.09.003
Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47:6645–53.
https://doi.org/10.1039/C8DT00838H DOI: https://doi.org/10.1039/C8DT00838H
Gupta A, Portales-Castillo I, Daher A, Kitchly A. Conventional chemotherapy nephrotoxicity. Adv Chronic Kidney Dis. 2021;28(5):402–14.
https://doi.org/10.1053/j.ackd.2021.08.001 DOI: https://doi.org/10.1053/j.ackd.2021.08.001
Esteve E, Bazin D, Jouanneau C, et al. How to assess the role of Pt and Zn in the nephrotoxicity of Pt anti-cancer drugs? An investigation combining uXRF and statistical analysis: part I: on mice. C.R. Chimie. 2016;19:1580–5.
https://doi.org/10.1016/j.crci.2016.03.014 DOI: https://doi.org/10.1016/j.crci.2016.03.014
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010;2(11):2490–528.
https://doi.org/10.3390/toxins2112490 DOI: https://doi.org/10.3390/toxins2112490
Li F, Livingstone MJ, Dong Z. Protection of kidneys by magnesium in cisplatin chemotherapy: a fight between two metals. Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F955–6.
https://doi.org/10.1152/ajprenal.00294.2017 DOI: https://doi.org/10.1152/ajprenal.00294.2017
Suppadungsuk S, Phitakwatchara W, Reungwetwattana T, et al. Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study). ESMO Open. 2022 Feb;7(1):100351.
https://doi.org/10.1016/j.esmoop.2021.100351 DOI: https://doi.org/10.1016/j.esmoop.2021.100351
Kimura T, Ozawa T, Hanai N, et al. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer. J Otolaryngol Head Neck Surg. 2018 Feb 2;47(1):10.
https://doi.org/10.1186/s40463-018-0261-3 DOI: https://doi.org/10.1186/s40463-018-0261-3
Duan ZY, Liu JQ, Yin P, Li JJ, Cai GY, Chen XM. Impact of aging on the risk of platinum-related renal toxicity: a systematic review and meta-analysis. Cancer Treat Rev. 2018 Sep;69:243–53.
https://doi.org/10.1016/j.ctrv.2018.07.002 DOI: https://doi.org/10.1016/j.ctrv.2018.07.002
Chen WY, Hsiao CH, Chen YC, et al. Cisplatin nephrotoxicity might have a sex difference. An analysis based on women’s sex hormone changes. J Cancer. 2017 Oct 23;8(19):3939–44.
https://doi.org/10.7150/jca.20083 DOI: https://doi.org/10.7150/jca.20083
Ben Ayed W, Ben Said A, Hamdi A, et al. Toxicity, risk factors and management of cisplatin-induced toxicity: a prospective study. J Oncol Pharm Pract. 2020 Oct;26(7):1621–9.
https://doi.org/10.1177/1078155219901305 DOI: https://doi.org/10.1177/1078155219901305
Sleijfer DT, Smit EF, Meijer S, Mulder NH, Postmus PE. Acute and cumulative effects of carboplatin on renal function. Br J Cancer. 1989 Jul;60(1):116–20.
https://doi.org/10.1038/bjc.1989.233 DOI: https://doi.org/10.1038/bjc.1989.233
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Suzanne van der Gaag, Mariette Labots, Eleonora L. Swart, Mirjam Crul
This work is licensed under a Creative Commons Attribution 4.0 International License.
